Today: 8 February 2026
Subscribe

AtlasClear (ATCH) Stock Skyrockets 50% on $20M Financing – Fintech Underdog Poised to Soar?

AtlasClear (ATCH) Stock Skyrockets 50% on $20M Financing – Fintech Underdog Poised to Soar?

Business Model & Market Position AtlasClear is a niche B2B fintech aiming to offer a one-stop clearing, brokerage and banking platform for smaller financial firms. According to the company, it is “building a cutting-edge, technology-enabled financial services platform to modernize trading, clearing, settlement and banking” globenewswire.com. Through its subsidiary Wilson-Davis & Co. (a full-service broker-dealer since 1968) AtlasClear provides correspondent clearing and trade execution. Management’s strategy is to expand this platform organically and via acquisitions: for example, it plans to acquire Commercial Bancorp of Wyoming (Farmers State Bank), a Federal Reserve member bank streetinsider.com, to gain FDIC/banking capabilities. The combined
9 October 2025
·
Shocking IRS Update: New 2026 Tax Brackets Slashed for Millions – Here’s How Much You’ll Save

Shocking IRS Update: New 2026 Tax Brackets Slashed for Millions – Here’s How Much You’ll Save

The IRS announced inflation-adjusted 2026 tax brackets and deductions, easing bracket creep irs.gov cbsnews.com. For example, a single earner making $50,000 will now fall in the 12% bracket (instead of 22%) cbsnews.com. The standard deduction rises to $32,200 for joint filers ($16,100 single) irs.gov. All seven marginal rates (10%–37%) remain in force under the new law, but higher income cutoffs apply irs.gov. Capital gains thresholds also jump: the 0% rate applies up to ~$49,450 (single) or $98,900 (couples) thefinancebuff.com, and the 15% bracket extends to ~$545,500/$613,700 thefinancebuff.com. These changes stem from the new “One Big Beautiful Bill” law (signed July
9 October 2025
CIFR Stock Skyrockets 320% After Google-Backed AI Mining Deal – Bubble or Boom?

CIFR Stock Skyrockets 320% After Google-Backed AI Mining Deal – Bubble or Boom?

Company Background & Business Model Cipher Mining is a pure-play Bitcoin miner that specializes in large-scale, energy-efficient data-center mining ts2.tech. It locates facilities “behind the meter” at low-cost renewable power sites in West Texas ts2.tech. Its flagship “Black Pearl” complex (Odessa, TX) is a 150 MW facility serving both Bitcoin mining and high-performance computing (HPC) ts2.tech. As of mid-2025, Cipher had deployed ~16.8 EH/s of mining capacity (with next-gen ASIC miners) ts2.tech and plans to reach ~23.5 EH/s by Q3’25 ts2.tech. To fund growth, it has a large 2.6 GW pipeline of additional power projects ts2.tech. In Q2’25 Cipher produced ~150 BTC and achieved $44 M
9 October 2025
·
MEDIROM (NASDAQ: MRM) Set for Takeoff: Series A Boost & Altman-Backed ‘Orb’ Deal Fuels 150% Upside

MEDIROM (NASDAQ: MRM) Set for Takeoff: Series A Boost & Altman-Backed ‘Orb’ Deal Fuels 150% Upside

Company Background & Business Model MEDIROM Healthcare Technologies (NASDAQ: MRM) is a Tokyo‑based provider of holistic health and wellness services. Founded in 2000, it operates 300+ Re.Ra.Ku branded relaxation salons across Japan medirom.co.jp, offering massage, aromatherapy and lifestyle therapy. These salons generate the bulk of revenues (47.3M of $52.7M in 2024) ir.medirom.co.jp. In parallel, since 2015 MEDIROM has built a Digital Preventative Healthcare arm. Key elements are: the Lav® on-demand health‐guidance app, and the MOTHER Bracelet®, a battery‑free wearable activity tracker. In 2023 it launched REMONY, a remote health monitoring service bundling the MOTHER Bracelet with corporate wellness programs medirom.co.jp.
9 October 2025
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reportsts2.techts2.techfiercebiotech.com; MarketBeat and DirectorsTalk analyst surveysmarketbeat.comdirectorstalkinterviews.com; Economic Times deal summaryeconomictimes.indiatimes.comeconomictimes.indiatimes.com; Business Wire legal alertbusinesswire.combusinesswire.com; and TradingView market datamarketbeat.comtradingview.com.
9 October 2025
·
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Company Profile – Background & Leadership Turn Therapeutics, Inc. is a Westlake Village, CA-based biotech company founded in 2015renaissancecapital.com. The company (formerly named Global Health Solutions, Inc.) officially rebranded to Turn Therapeutics in Sept 2025 ahead of its Nasdaq listingstockanalysis.com. Turn’s mission is to “turn the tides” in medicine by developing technologies that heal, not just manage, challenging traditional treatmentsbenzinga.com. CEO Bradley Burnam (the founder) leads a lean operation “built on a shoestring, with an absolute disdain for waste,” as he emphasized during the Nasdaq bell-ringing ceremonybenzinga.com. Burnam and his team bring a “patient-first” approach and a frugal business model to drug development, aiming to maximize R&D output
9 October 2025
·
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 (nexiguran ziclumeran) for transthyretin amyloidosis (ATTR) and NTLA-2002 (lonvoguran ziclumeran) for hereditary angioedema (HAE) ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to
9 October 2025
·
Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Import Fair 2025: Turning Imports into Local Industry Uzbekistan’s capital Tashkent buzzed with business activity as the country opened the First International Uzbek Import Fair 2025. The exhibition, held at the Uzexpocentre on October 7–9, is a cornerstone of President Shavkat Mirziyoyev’s industrial strategy to boost local production. Deputy PM Jamshid Khodjaev, inaugurating the fair, emphasized its mission to deepen industrial cooperation, support domestic manufacturers, and promote import substitution uzdaily.uz. The theme “Optimizing Imports and Increasing Local Content” underscores a shift in policy: instead of curbing imports via tariffs or bans, Uzbekistan wants to partner with foreign firms to produce
9 October 2025
United Airlines Stock Skyrockets on Travel Boom: Is $130 Next for UAL?

United Airlines Stock Skyrockets on Travel Boom: Is $130 Next for UAL?

Stock Price & Recent Performance As of market close Oct 8, 2025, UAL traded around $98.09 reuters.com, a ~1.5% gain for the day. In early pre-market Oct 9, it had jumped ~6% to ~$104 stockanalysis.com. Over the past week, UAL shares have rebounded from recent lows near ~$94 (Oct 2) to fresh highs around $99–100. The stock’s 6-month chart shows a rally to a mid-September peak (~$109) followed by a pullback; current technical indicators (see below) suggest mild momentum. UAL trades well above its pandemic lows and has outperformed some broader indices this year (its 52-week high is $116 reuters.com).
9 October 2025
·
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Company Overview: A Near-Patient Diagnostics Specialist Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings stocktitan.net. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis stocktitan.net. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result” analyzer that uses disposable cartridges to measure key biomarkers from a patient’s blood sample in minutes bluejaydx.com bluejaydx.com. Symphony’s first target analyte is interleukin-6 (IL-6), an inflammatory marker that rises during infection and sepsis. In hospitals today, diagnosing sepsis early
9 October 2025
··
AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

Latest News (Oct 7–Oct 9, 2025) Stock Performance & Technical Analysis After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 insidermonkey.com, putting it near the middle of its volatile 52-week range ($3.97 – $10.87) ts2.tech. For context, RXRX had traded in the double-digits when AI hype in biotech peaked earlier in the year, then slid into the high-$3s during industry sell-offs ts2.tech. Even after this week’s pop, shares remain ~30% lower than a year ago (amid a broader biotech downturn) ts2.tech. Such dramatic swings
9 October 2025
···
American Airlines (AAL) Stock Takes Off on Travel Demand – Will It Keep Climbing or Hit Turbulence?

American Airlines (AAL) Stock Takes Off on Travel Demand – Will It Keep Climbing or Hit Turbulence?

Stock Price and Recent Performance American Airlines’ stock has been on a turbulent ride in 2025. After starting the year in the high teens, AAL has sunk into the low double-digits – recently closing around $11.81 marketbeat.com. The slide accelerated in September amid soft travel demand and pessimistic guidance. As of early October, shares were down over 34% year-to-date (vastly underperforming the S&P 500) and about 15% lower in the past month alone marketbeat.com. This steep drop reflects both company-specific challenges and broader sector headwinds (from rising costs to economic jitters). This week, however, brought a glimmer of relief. American’s
9 October 2025
··
Serve Robotics (SERV) Stock Soars on DoorDash Deal – The Next Big Bet in AI Delivery?

Serve Robotics (SERV) Stock Soars on DoorDash Deal – The Next Big Bet in AI Delivery?

Latest News & Developments (October 2025) Serve Robotics grabbed headlines this week with a major new partnership announcement. On October 9, 2025, the company revealed a deal with DoorDash to deploy Serve’s sidewalk delivery robots for food orders on the DoorDash platform investing.com. Initially rolling out in Los Angeles, the pilot means DoorDash customers from select restaurants may have their meals delivered by a Serve robot investing.com. This is a strategic expansion beyond Serve’s exclusive relationship with Uber Eats to date. “This partnership enables us to go to cities where DoorDash is the dominant player… we’re looking for more demand,
9 October 2025
·
Gold Hits $4,000 Record, Silver Soars to $50 – Rally to Continue or Crash Ahead?

Gold Hits $4,000 Record, Silver Soars to $50 – Rally to Continue or Crash Ahead?

Precious Metals Skyrocket to Historic Highs Gold and silver have been on a record-breaking tear in 2025. Gold entered the year around $2,800 and by October blasted past the $4,000/oz milestone – an unprecedented level ts2.tech ts2.tech. On October 7–8, spot gold surged to an all-time high near $4,078 before settling around $4,038 by Oct. 9 ts2.tech reuters.com. This ~53% year-to-date jump is gold’s steepest annual gain since 1979 reuters.com, vastly outpacing equities (the S&P 500 is up ~15% YTD) ts2.tech. “$4,000 an ounce seemed far-fetched at the start of the year… but after a ~50% rally, here we are,”
9 October 2025
·
Jefferies Scrambles as First Brands’ $10 Billion Bankruptcy Reveals $2.3 Billion in ‘Vanished’ Debt

Jefferies Scrambles as First Brands’ $10 Billion Bankruptcy Reveals $2.3 Billion in ‘Vanished’ Debt

First Brands’ Debt-Fueled Rise and Spectacular Fall First Brands Group’s journey from industry consolidator to bankruptcy cautionary tale was swift and dramatic. The company – a leading supplier of replacement auto parts like oil filters, brake pads and windshield wipers – grew aggressively through debt-financed acquisitions in the 2010s Livemint. By 2025, it owned well-known aftermarket brands such as Raybestos (brake components), TRICO (wiper blades) and FRAM (engine filters), selling through major retailers like Walmart and AutoZone ts2.tech. However, this rapid expansion came at the cost of a towering debt load that far outpaced its earnings. Over the summer of
9 October 2025
···
Powell’s Next Move Could Make or Break 2025’s Record Stock Rally

Powell’s Next Move Could Make or Break 2025’s Record Stock Rally

Record Highs Amid a Tech-Fueled Rally Wall Street’s momentum in 2025 is undeniable – and increasingly historic. Stocks have been on a tear, repeatedly smashing records. After seven consecutive daily gains to start October, the market took only a brief pause before charging higher again. On October 8, the S&P 500 and Nasdaq Composite clinched fresh all-time highs (around 6,754 and 23,043 respectively) ts2.tech. These milestones extend what has already been a remarkable year; the S&P is up roughly 18% year-to-date, with the Nasdaq not far behind ts2.tech. Even the blue-chip Dow Jones Industrial Average, while slightly lagging, is near
9 October 2025
·
Nvidia’s $2B Bet on Reflection AI Shakes Up the Global AI Race

Nvidia’s $2B Bet on Reflection AI Shakes Up the Global AI Race

Reflection AI’s $2B Funding Frenzy It’s official: Reflection AI has secured one of the largest funding rounds ever for a young tech startup – $2 billion in fresh capital led by Nvidia techmeme.com. The New York Times first reported the blockbuster raise, valuing the one-year-old company at roughly $8 billion techmeme.com. To put that in perspective, Reflection was valued at only ~$545 million as recently as March techmeme.com. In other words, its paper valuation has leapt nearly 15× in just six months, a virtually unheard-of jump. The NYT called this “the latest sign of investor fervor” around AI, even as
9 October 2025
···
Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed, Inc. (NYSE: WOLF) has seen a stunning reversal in fortune. As of October 9, 2025, the stock trades around $30.36 per share, giving the company a market capitalization of roughly $0.7–0.8 billion reuters.com companiesmarketcap.com. Just weeks ago, Wolfspeed emerged from Chapter 11 bankruptcy after cutting its debt by ~70% and interest costs by ~60% ts2.tech. This financial restructuring wiped out most of the old equity – existing shareholders were left with only ~3–5% of the reorganized company ts2.tech – but set the stage for a dramatic stock rally. In fact, WOLF exploded over 1,000% intraday on September 29, 2025
9 October 2025
·
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Company Overview: Pioneering T-Cell Therapies for Cancer Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor (TCR) engineered cell therapies to fight cancer ts2.tech. The company’s mission has been to “redefine how some of the most challenging-to-treat solid tumors are treated” by harnessing patients’ own T-cells and genetically equipping them to target cancer cells Adaptimmune. Adaptimmune’s proprietary platform, known as SPEAR T-cells (Specific Peptide Enhanced Affinity Receptor), allows it to design TCRs that recognize tumor-specific antigens (such as MAGE-A4 or NY-ESO-1) and arm patient T-cells with these receptors ts2.tech ts2.tech. In effect, it’s analogous to
9 October 2025
Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari in the Headlines: New Strategic Plan & Stock Shock In early October 2025, Ferrari N.V. held a high-profile Capital Markets Day (investor day) in Maranello, unveiling its 2030 strategic plan and updated guidance. The event proved dramatic – Ferrari’s stock plunged nearly 12% in its worst single-day drop since the company’s 2015 IPO reuters.com. Shares were briefly halted after sliding by double-digits on October 9 reuters.com, and ultimately closed the day deep in the red. This sell-off was sparked by a mix of surprising strategic pivots and cautious long-term targets that rattled some investors, despite Ferrari simultaneously raising near-term
9 October 2025
··
1 … 1,472 1,473 1,474 1,475 1,476 … 1,636

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop